Cytokinetics, Incorporated
CYTK · Healthcare
$71.40
Φόρτωση γραφήματος…
Νέα
Τελευταίοι τίτλοι για αυτή τη μετοχή
Will Camzyos' Long-Term Benefits Strengthen BMY's Growth Outlook?
Bristol Myers Squibb's Camzyos demonstrated durable reductions in LVOT obstruction over five years with 97.4% of patients achieving target gradients. Sales surged 74% year-over-year to $729 million in H1 2026. The company seeks FDA approval for adolescents with a decision expected by September 30, 2026. However, competition is intensifying with Cytokinetics' Myqorzo approved in December 2025 and Edgewise Therapeutics advancing EDG-7500 in clinical trials.
Cytokinetics to Participate in September Investor Conferences
Cytokinetics announced that management will participate in multiple investor conferences in September 2026. The company highlighted positive results from its ACACIA-HCM Phase 3 clinical trial for aficamten in non-obstructive hypertrophic cardiomyopathy (nHCM), with plans to submit a Supplemental New Drug Application in Q4 2026. The trial demonstrated statistically significant improvements in both patient-reported and physician-assessed endpoints.
Can CYTK's Aficamten Strengthen Its HCM Growth Prospects?
Cytokinetics announced additional positive results from ACACIA-HCM and MAPLE-HCM studies showing aficamten improved cardiac structure and diastolic function in non-obstructive HCM patients, and outperformed metoprolol in obstructive HCM. The company plans to file for nHCM approval in Q4 2026, potentially expanding the drug's addressable market. Myqorzo received FDA approval in December 2025 for obstructive HCM treatment.
Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026
Cytokinetics presented additional clinical trial results for aficamten (MYQORZO) at the ESC Congress 2026. ACACIA-HCM data showed aficamten improved cardiac structure and diastolic function in non-obstructive HCM patients beyond exercise capacity improvements. MAPLE-HCM analysis demonstrated aficamten outperformed metoprolol across different pre-trial treatment groups in obstructive HCM patients. The company plans to submit a Supplemental New Drug Application for non-obstructive HCM in Q4 2026.
Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700
Cytokinetics CEO Robert Blum exercised 7,500 stock options at a strike price of $10.60 and sold them at a weighted-average price of $76.76, generating $575,700. Despite the sale, Blum retains substantial equity holdings of 377,820 direct shares and 4,166 indirect shares, indicating continued alignment with shareholders. Analysts view the transaction as routine profit-taking given the stock's 100% gain over the past 12 months, with 91% of analysts rating the stock a buy and a median price target of $107.50.